Physician profile
Faisal Paracha
NPI 1346299971
$13,588.60
in general payments reported to CMS, 2019-2025
41 companies · $440 in 2025
The $440 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $639 · 2021: $1,194 · 2022: $125 · 2023: $319 · 2024: $156 · 2025: $440.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $899 · Education: $17.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $898.71 |
| Education | $17.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $3,409.84 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $3,087.34 | 2019-2025 | Enhertu, Imfinzi |
| Exelixis INC. | $2,791.14 | 2019-2025 | Cabometyx |
| Blueprint Medicines Corporation | $1,182.00 | 2021 | |
| Novartis Pharmaceuticals Corporation | $363.23 | 2019-2024 | |
| Incyte Corporation | $286.19 | 2019-2025 | Jakafi, Zynyz, Monjuvi |
| Amgen INC. | $272.54 | 2019-2023 | Blincyto, Kyprolis |
| Beigene USA, INC. | $229.00 | 2022-2023 | Brukinsa |
| Celgene Corporation | $198.93 | 2019 | |
| Seagen INC. | $158.28 | 2019-2020 | |
| Beone Medicines USA, INC. | $150.00 | 2025 | Brukinsa |
| Pfizer INC. | $145.74 | 2019-2020 | |
| Acrotech Biopharma INC. | $107.60 | 2021-2025 | Beleodaq |
| Bayer Healthcare Pharmaceuticals INC. | $103.82 | 2019 | |
| Lilly USA, LLC | $97.29 | 2019-2020 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Faisal Paracha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.